Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactive oxygen species  by Zhou, Jin et al.
S
c
J
S
a
b
S
c
h
•
•
•
•
a
A
R
R
A
A
K
S
C
A
R
(
0
hToxicology Letters 222 (2013) 139– 145
Contents lists available at ScienceDirect
Toxicology  Letters
jou rn al hom epage: www.elsev ier .com/ locate / tox le t
alinomycin  induces  apoptosis  in  cisplatin-resistant  colorectal  cancer
ells  by  accumulation  of  reactive  oxygen  species
in  Zhoua,1,  Pu  Lib,1, Xiaofeng  Xuea, Songbing  Hea,  Yuting  Kuanga, Hong  Zhaoa,
haoji  Chena,  Qiaoming  Zhia,∗, Xiaobo  Guoc,∗∗
Department of General Surgery, The First Afﬁliated Hospital of Soochow University, Suzhou, 215006, China
Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Department of Surgery, Ruijin Hospital, School of Medicine,
hanghai Jiao Tong University, Shanghai, 200025, China
Department of Gastrointestinal Surgery, Provincial Hospital Afﬁliated to Shandong University, Jinan, 250021, China
 i  g  h  l  i  g  h  t  s
Cisp-resistant  SW620  cells  maintained  as  a relative  quiescent  state  (G0/G1  arrest).
Cisp-resistant  SW620  cells  displayed  more  stem-like  signatures.
Cisp-resistant  SW620  cells  were  sensitive  to  salinomycin.
Salinomycin  induced  more  apoptosis  in Cisp-resistant  SW620  cells.
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a  b  s  t  r  a  c  t
Postoperative  chemotherapy  for Colorectal  cancer  (CRC)  patients  is  not  all  effective  and  the main
reason  might  lie in  cancer  stem  cells  (CSCs).  Emerging  studies  showed  that CSCs  overexpress  some
drug-resistance  related  proteins,  which  efﬁciently  transport  the  chemotherapeutics  out of  cancer  cells.
Salinomycin,  which  considered  as  a novel  and  an  effective  anticancer  drug,  is  found  to  have  the  ability
to  kill  both  CSCs  and  therapy-resistant  cancer  cells.  To  explore  the  potential  mechanisms  that  salino-
mycin  could  speciﬁcally  target  on  therapy-resistant  cancer  cells  in  colorectal  cancers,  we  ﬁrstly  obtained
cisplatin-resistant  (Cisp-resistant)  SW620  cells  by repeated  exposure  to 5 mol/l  of cisplatin  from  an
original  colorectal  cancer  cell  line.  These  Cisp-resistant  SW620  cells,  which  maintained  a  relative  quies-
cent state  (G0/G1  arrest)  and  displayed  stem-like  signatures  (up-regulations  of  Sox2,  Oct4,  Nanog,  Klf4,
Hes1,  CD24,  CD26,  CD44,  CD133,  CD166,  Lgr5,  ALDH1A1  and  ALDH1A3  mRNA  expressions)  (p <  0.05),
were  sensitive  to salinomycin  (p <  0.05).  Salinomycin  did  not  show  the  inﬂuence  on the cell cycle  of  Cisp-
resistant  SW620  cells  (p > 0.05),  but could  induce  cell  death  process  (p < 0.05),  with  increased  levels  of  LDH
release and  MDA  contents  as  well  as down-regulations  of  SOD  and  GSH-PX  activities  (p  < 0.05).  Our  data
also showed  that the pro-apoptotic  genes  (Caspase-3,  Caspase-8,  Caspase-9  and  Bax)  were  up-regulated
and  the anti-apoptotic  gene  Bcl-2  were  down-regulated  in  Cisp-resistant  SW620  cells  (p  < 0.05).  Accumu-
lated  reactive  oxygen  species  and dysregulation  of  some  apoptosis-related  genes  might  ultimately  lead
to apoptosis  in Cisp-resistant  SW620  cells.  These  ﬁndings  will  provide  new  clues  for  novel  and  selective
chemotherapy  on  cisplatin-resistant  colorectal  cancer  cells.
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1. Introduction
Colorectal cancer (CRC) is the third most common malignancy
worldwide with increasing incidence over the past years (Sung
et al., 2005). Surgical resection remains the most effective treat-
ment for CRC. However, after the radical surgery, the overall
Open access under CC BY-NC-ND license.ﬁve-year survival rate still remains poor. Most of the CRC patients
die from recurrence and metastasis (Stillwell et al., 2011). Fur-
thermore, postoperative chemotherapy for CRC patients is not all
effective. A small proportion of patients are naturally tolerant to
NC-ND license.
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ome traditional chemotherapeutics, and the main reason might
ie in cancer stem cells (CSCs) (Morrison et al., 2011).
CSCs are a small proportion of cancer cells that exist in the
ancer cell population, that have the ability to self-renew and
ndergo differentiation. And CSCs are found to be resistant to con-
entional cancer treatments, including chemotherapeutic drugs
nd radiation therapy (Dalerba et al., 2007; Santin, 2009; Tan
t al., 2006). CSCs highly express ATP-binding drug transporters.
tandard chemotherapy or radiation therapy is effective in killing
he bulk of the tumor but not the CSCs. The mortality of cancer
emains high, because conventional therapies often fail to eradi-
ate the CSC population, allowing relapse to occur (Lu et al., 2011).
lternatively, tumor drug-resistant cells induced by traditional
hemotherapeutics also present cancer stem-like characteristics
Gopalan et al., 2013). So novel therapeutic strategies targeting
peciﬁcally on CSCs are urgently needed.
In 2009, Gupta et al. identiﬁed salinomycin by a high throughput
creening that could potentially be used to target breast CSCs, and
t killed breast CSCs at least 100 times more effectively than pacli-
axel in mice (Gupta et al., 2009). Emerging evidences showed that
alinomycin could effectively kill various types of cancer stem-like
ells, including gastric cancer (Zhi et al., 2011), pancreatic can-
er (He et al., 2013; Zhang et al., 2011), hepatocellular carcinoma
Wang et al., 2012), ovarian cancer (Zhang et al., 2012), prostate
ancer(Ketola et al., 2012; Kim et al., 2011) and some other types
f malignancy (Kuo et al., 2012; Scherzed et al., 2013). However,
he mechanism underlying salinomycin and drug-resistant cells in
RC has not been studied yet.
In our study, we continously treated the coloretal cancer cells
y 5 mol/l of cisplatin and successfully obtained the Cisp-resistant
W620 cells. Then we detected some speciﬁc stem cell markers to
onﬁrm whether Cisplatin-resistant SW620 cells displayed a stem-
ike signature. In order to discuss the killing effect of salinomycin
n Cisplatin-resistant SW620 cells, we treated Cisplatin-resistant
W620 cells and orginal SW620 cells with a certain concentration
f salinomycin, and observed the change of cell cycle and apopto-
is. Meanwhile, we also evaluated the levels of oxidative stress
arkers (LDH release, MDA  contents, SOD and GSH-PX activities)
nd apoptosis-related genes (Caspase-3, Caspase-8, Caspase-9, Bcl-
 and Bax) to explore the possible mechanism of salinomycin on
isp-resistant SW620 cells.
. Materials and methods
.1. Chemicals and cell culture
Cisplatin and salinomycin were obtained from Sigma-Aldrich (Sigma, USA).
uman colorectal cancer cell line SW620 was purchased from American Type Cul-
ure Collection (ATCC, Manassas, VA, USA) and cultured in RPMI-1640 medium
Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (Gibco, Invitrogen) in
 humidiﬁed atmosphere of 5% CO2 at 37 ◦C. Cells were in the logarithmic phase of
rowth for all experiments.
.2. 50% inhibiting concentration (IC50) and cell proliferation analysis by cell
ounting kit-8
For cisplatin or salinomycin IC50 analysis in SW620 cells or Cisp-resistant
W620 cells, cells (1 × 104/well) were cultured in 96-well plates and treated with
ifferent chemotherapeutics (cisplatin, salinomycin) in different concentrations for
8  h. Then 20 l of cell counting kit-8 (CCK-8, Dojindo, Kumamoto, Japan) was added
nto each of the 96-wells. After 4 h incubation at 37 ◦C, the optical density (OD) val-
es were detected at 450 nm using the scan reader (Labsystems, Santa Fe, NM,  USA).
ell  growth inhibiting rates were described as cell inhibiting curves and the IC50
arameters (inhibiting concentration of 50% cells) were evaluated by Xlﬁt 5.2 soft-
are (IDBS, UK). For cell proliferation analysis, SW620 cells or Cisp-resistant SW620
ells (5 × 103/well) were also seeded in 96-well plates in serum-containing medium
nd treated with cisplatin (5 mol/l, according to the calculated IC50 values of cis-
latin in SW620 cells) for 0, 12, 24, 48, 72 and 96 h. Then 20 l cell counting kit-8 was
dded into each of the 96-wells. After 4-h incubation at 37 ◦C, the coloring reactions
ere also quantiﬁed at 450 nm.rs 222 (2013) 139– 145
2.3. Continuous treatment with cisplatin
SW620 cells were grown in 10-cm culture dishes and treated with proper con-
centration of cisplatin (5 mol/l) according to the results of IC50. We  replaced the
culture medium every 7 day. After continuous exposure to non-lethal levels of cis-
platin for 3 months, the Cisp-resistant SW620 cells were obtained (Fig. 1).
2.4. Real-time PCR detection
Total RNA was extracted using Trizol solution (Invitrogen,USA) according to
the manufacturer’s instructions. The quantities and qualities of isolated RNAs
were evaluated using absorbance measurements at 260 and 280 nm.  Then reverse
transcription (RT) was performed in a 20-l reaction system using the ReverAid
First Stand cDNA Synthesis (Thermo Scientiﬁc, Mountain View, CA, USA). Primer
sequences for GAPDH were 5′-GGACCTGACCTGCCGTCTAG-3′ (Forward) and 5′-
GTAGCCCAGGATGCCCTTGA-3′ (Reverse). Other primer sequences were all listed in
Table 1. RT-PCR with SybGreen I (Generay Bio Co., Shanghai, China) was performed
using the 7500 real-time PCR system (Applied Biosystems, Hayward, CA, USA) with
the follow program: initial denature at 95 ◦C for 5 min, followed by 40 cycles for 95 ◦C
for  15 s, annealing at 60 ◦C for 60 s, and 72 ◦C for 30 s. All samples were processed
in triplicate. The mRNA expression of each gene was calculated using the relative
quantitative 2−CT method.
2.5. Cell cycle analysis
Cells were seeded at 5 × 104 per well in 6-well plates in triplicate. 48 h after
salinomycin treatment (0.25 mol/l) or not, SW620 cells and Cisp-resistant SW620
cells were collected, washed twice in 1x PBS, mixed in 200 l of 1x binding buffer,
and incubated at room temperature for 15 min with 250 g/ml propidium iodide (PI)
(Sigma, St. Louis, USA) and 5 g/ml Rnase (BD Biosciences, USA). The cell cycle was
analyzed by FACSscan ﬂow cytometer. Each treatment was performed in triplicate.
2.6. Hoechst33342 staining
Cells were seeded at 5 × 104 per well in 6-well plates in triplicate. 48 h after sali-
nomycin treatment (0.25 mol/l) or not, SW620 cells and Cisp-resistant SW620 cells
(2  × 105ml–1) were harvested and added 10 l of Hoechst33342 solution (Keygen
Biotech, Nanjing, China) for 15 min  in the dark at 37 ◦C. After centrifuging for 5 min
and  washing with 1x PBS, 1 ml  of Buffer A solution (Keygen Biotech, Nanjing, China)
was added at room temperature and mixed. Finally, 20 l of cell pellet was dropped
on  a glass slide and the image was observed under an inverted phase-contrast
ﬂuorescence microscope (Olympus, Japan).
2.7. Annexin-V-PE staining
Cells were seeded at 5 × 104 per well in 6-well plates in triplicate. 48 h after
salinomycin treatment (0.25 mol/l) or not, SW620 cells and Cisp-resistant SW620
cells were collected. Cells were double stained with Annexin-V-PE (BD Pharmin-
gen, San Jose, CA, USA) and propidium iodide (PI) (Sigma, St. Louis, USA) following
the manufacturer’s instructions. Cell apoptosis was determined by FACSscan ﬂow
cytometer. Each treatment was performed in triplicate.
2.8. LDH release assay
LDH activity was evaluated using a colorimetric LDH assay. Cell were seeded
at  1 × 104cells/200 l in each 96-well plate and pre-treated with salinomycin
(0.25 mol/l) for 48 h. Brieﬂy, 100 l supernatant was  transferred from each well
to  a 96-well plate and 100 l freshly reaction mixture was added to each well. After
30 min of incubation at room temperature in the dark, the optical density (OD) val-
ues  were detected at 490 nm using the scan reader (Labsystems, Santa Fe, NM, USA).
The amount of LDH was calculated as a percent compared to the total amount of
LDH present in cell treated with 1% Triton-X 100 (Solarbio, Shanghai, China).
2.9. Detections of oxidative stress markers (MDA, SOD and GSH-PX)
Cells were seeded at 5 × 104 per well in 6-well plates in triplicate. 48 h after sali-
nomycin treatment (0.25 mol/l), cells were harvested and the extracted proteins
were quantiﬁed. We measured the MDA  contents, SOD and GSH-PX activities with
commercial reagent kits purchased from Nanjing Jiancheng Bioengineering Institute
(Nanjing, China).
2.10. Western blot analysis
Cells were harvested and lysed with mammalian protein extraction reagent
(Pierce, Rockford, IL, USA). Total protein (30 g) was separated on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to
Immobilon-P Transfer Membrane (Millipore, Ballerica, USA). Then the membranes
were blocked for 2 h with 5% non-fat dry milk in PBS and incubated with primary
antibodies (Caspase-3, Caspase-8 and Caspase-9, Bioworld Technology, USA; Bax
and  Bcl-2, Cell Signaling Technology, USA). Second antibodies were conjugated to
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orse radish peroxidase (HRP) and signals were detected by chemiluminescence.
rotein levels were normalized to the total glyceraldehyde-3-phosphate dehydro-
enase (GAPDH) using a rabbit monoclonal anti-GAPDH antibody (Sigma, USA).
.11. Statistical analysis
Statistical analysis was  performed with SPSS 17.0 software (SPSS Inc, Chicago,
SA). Statistically signiﬁcant differences were estimated using one-way analysis
f  variance followed by Student t-test. Data was presented as the mean ± SD and
 < 0.05 was considered as signiﬁcant.
. Results
.1. Identiﬁcation of Cisp-resistant SW620 cells
Based on the IC50 value of SW620 cells to cis-
latin(6.11 ± 1.52 mol/l), we selected a proper concentration
5 mol/l) to induce Cisp-resistant cells. After continuous treat-
ent with cisplatin for 3 months, we successfully obtained the
isp-resistant SW620 cells (Fig. 1). Then we  used a series of
xperiments to identify that whether our induced cells were
elatively resistant to cisplatin. As shown in Fig. 2A and B, we
ompared the IC50 values between SW620 (6.11 ± 1.52 mol/l)
nd Cisp-resistant SW620 cells (51.12 ± 4.98 mol/l). Our results
emonstrated that Cisp-resistant SW620 cells were relatively
olerant to the toxic effects of cisplatin. Moreover, with a certain
oncentration of cisplatin treatment (5 mol/l), we  compared
he optical density (OD) values, and found that the proliferation
ctivity of Cisp-resistant cells was very stable, while the prolifer-
tion activity of SW620 cells decreased at 12, 24, 48, 72 and 96 h
p < 0.05) (Fig. 2C). Our results manifested that the Cisp-resistant
W620 cells could be relatively resistant to cisplatin treatment
nd suitable for our further studies.
able 1
eal-time PCR primer sequences.
Gene name Primer sequence (5′–3′) 
Sox2 F GCCGAGTGGAAACTTTTGTCG 
R  GCAGCGTGTACTTATCCTTCTT 
Oct4  F CTTGAATCCCGAATGGAAAGGG 
R  GTGTATATCCCAGGGTGATCCTC 
Nanog  F TAACCTTGGCTGCCGTCTCTGG 
R  AAGCCTCCCAATCCCAAACAATACG 
Klf4  F CGGACATCAACGACGTGAG 
R  GACGCCTTCAGCACGAACT 
Hes1  F TCAACACGACACCGGATAAAC 
R  GCCGCGAGCTATCTTTCTTCA 
MDR1  F CTGTGGATCACCGAGAGGG 
R  ACAGGCGATGGTCCAGTAGA 
MRP1  F GAGGAACCATATTACAGGTCCGT 
R  AGGGGATCATCGAAGAGGTAAAT 
LRP  F CCCGCGACAGTTTCCAATGA 
R  GGCGTTGAGACCAGGTTTCA 
CD24  F CTCCTACCCACGCAGATTTATTC 
R  AGAGTGAGACCACGAAGAGAC 
CD26  F TACAAAAGTGACATGCCTCAGTT 
R  TGTGTAGAGTATAGAGGGGCAGA 
CD44  F CTGCCGCTTTGCAGGTGTA 
R  CATTGTGGGCAAGGTGCTATT  3 months, Cisp-resistant SW620 cells were obtained.
3.2. Expressions of CSCs related genes in Cisp-resistant SW620
cells
In order to better understand the possible and unique traits
of Cisp-resistant SW620 cells that distinguished from the origi-
nal SW620 cells. We  detected the mRNA expressions of some key
CSCs related genes by Real-time PCR, including stem cell related
transcription factors (Sox2, Oct4, Nanog, Klf4 and Hes1), surface
biomarkers (CD24, CD26, CD44, CD133, CD166, Lgr5), functional
markers (ALDH1A1 and ALDH1A3), and drug resistance-related
proteins (MDR1, MRP1 and LRP) in SW620 cells and Cisp-resistant
SW620 cells. Our results in Fig. 2D and E showed that the express-
ing levels of Sox2, Oct4, Nanog, Klf4, Hes1, MDR1, MRP1, LRP, CD24,
CD26, CD44, CD133, CD166, Lgr5, ALDH1A1 and ALDH1A3 were sig-
niﬁcantly higher in Cisp-resistant SW620 cells than those in SW620
cells respectively (p < 0.05), but there was  no difference of ALDH2
mRNA expressions between SW620 cells and Cisp-resistant SW620
cells (p > 0.05).
3.3. Salinomycin did not change cell cycle in Cisp-resistant
SW620 cells
After salinomycin treatment or not, we  examined the change
of cell cycle between SW620 and Cisp-resistant SW620 cells.
As shown in Fig. 3A, Our results showed that repeated treat-
ment of cisplatin could block the cell cycle and induce G0/G1
phase arrest, while cells of S and G2/M phase decreased accord-
ingly (p < 0.05). This phenomenon meant that Cisp-resistant
SW620 cells maintained a relative quiescent state compared
to original SW620 cells. We  also examined the change of cell
cycle after salinomycin treatment both in SW620 and Cisp-
resistant SW620 cells by ﬂow cytometry. Our data indicated that
salinomycin did not change the process of cell cycle including
Gene name Primer sequence (5′–3′)
CD133 F TTCTTGACCGACTGAGACCCA
R TCATGTTCTCCAACGCCTCTT
CD166 F TCCTGCCGTCTGCTCTTCT
R TTCTGAGGTACGTCAAGTCGG
Lgr5 F CTCCCAGGTCTGGTGTGTTG
R GAGGTCTAGGTAGGAGGTGAAG
ALDH1A1 F AGCCTTCACAGGATCAACAGA
R GTCGGCATCAGCTAACACAA
ALDH1A3 F GCCCTTTATCTCGGCTCTCT
R CGGTGAAGGCGATCTTGT
ALDH2 F ACCTGGTGGATTTGGACATGGTCC
R TCAGGAGCGGGAAATTCCACGGA
Caspase-3 F CATGGAAGCGAATCAATGGACT
R CTGTACCAGACCGAGATGTCA
Caspase-8 F CGGACTCTCCAAGAGAACAGG
R TCAAAGGTCGTGGTCAAAGCC
Caspase-9 F CTCAGACCAGAGATTCGCAAAC
R GCATTTCCCCTCAAACTCTCAA
Bcl-2 F GGTGGGGTCATGTGTGTGG
R CGGTTCAGGTACTCAGTCATCC
Bax F CCCGAGAGGTCTTTTTCCGAG
R CCAGCCCATGATGGTTCTGAT
142 J. Zhou et al. / Toxicology Letters 222 (2013) 139– 145
Fig. 2. (A) Cell inhibiting curves were drawn after treatment with different concentrations of cisplatin for 48 h. (B) The IC50 values of cisplatin for 48 h between SW620
cells  and Cisp-resistant SW620 cells were compared. (C) Cisplatin (5 mol/l) could inhibit the growth of SW620 cells by CCK-8 assay, but could not inhibit the growth of
Cisp-resistant SW620 cells. (D) Real-time PCR analysis showed that the expressing levels of Sox2, Oct4, Nanog, Klf4, Hes1, MDR1, MRP1, LRP were signiﬁcantly higher in
Cisp-resistant SW620 cells than those in SW620 cells. (E) Real-time PCR analysis showed that the expressing levels of CD24, CD26, CD44, CD133, CD166, Lgr5, ALDH1A1 and
ALDH1A3 were signiﬁcantly higher in Cisp-resistant SW620 cells than those in SW620 cells, but there was no difference in ALDH2 mRNA expressions. (* p < 0.05).
Fig. 3. (A) Compared to original SW620 cells, Cisp-resistant SW620 cells maintained a relative quiescent state. Cells of G0/G1 phase increased, while cells of S and G2/M
phase  decreased in Cisp-resistant SW620 cells. But salinomycin did not change the cell cycle of SW620 cells and Cisp-resistant SW620 cells. (B) By Hoechst33342 staining,
salinomycin increased apoptotic cells in Cisp-resistant SW620 cells than those in SW620 cells. Arrows represented apoptotic cells. (C) By Annexin-V-PE staining, salinomycin
signiﬁcantly increased cell apoptosis in Cisp-resistant SW620 cells than those in SW620 cells. (* p < 0.05; # p > 0.05).
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Fig. 4. (A) Compared to original SW620 cells, salinomycin treatment increased the release of LDH in Cisp-resistant SW620 cells. (B) Salinomycin treatment signiﬁcantly
increased MDA  contents in Cisp-resistant SW620 cells. (C) and (D) Salinomycin treatment down-regulated SOD and GSH-PX activities in Cisp-resistant SW620 cells than
those  in SW620 cells. (E) Cell inhibiting curves were drawn after treatment with different concentrations of salinomycin for 48 h in SW620 cells and Cisp-resistant SW620
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ensitive to Cisp-resistant SW620 cells. (G) Real-time PCR analysis showed that aft
ax  were signiﬁcantly up-regulated in Cisp-resistant SW620 cells than those in SW
0/G1, S and G2/M phase in SW620 cells (p > 0.05). Meanwhile,
alinomycin also did not inﬂuence the cell cycle in Cisp-resistant
W620 cells (p > 0.05).
.4. Salinomycin increased cell apoptosis in Cisp-resistant SW620
ells by Hoechst33342 staining
After continuous salinomycin treatment for 48 h, the apoptotic
ells were observed under the microscope and counted randomly
t least 100 cells in one ﬁeld. Our results showed that the number
f apoptotic cells which were stained by Hoechst33342 was signif-
cantly increased in Cisp-resistant SW620 cells (20.20 ± 3.72) than
hat of SW620 cells (9.40 ± 2.07) per 100 cells (p < 0.05) (Fig. 3B).
.5. Salinomycin induced cell apoptosis in Cisp-resistant SW620
ells by Annexin-V-PE staining
After treatment with salinomycin for 48 h, we used ﬂow cyto-
etric analysis to detect the cell apoptosis both in SW620 cells and
isp-resistant SW620 cells. We  found that the cell apoptotic rate in
isp-resistant SW620 cells (37.82 ± 3.63%) was signiﬁcantly higher
han that of SW620 cells (16.78 ± 2.56%) (p < 0.05) (Fig. 3C).
.6. Salinomycin increased LDH release and MDA  contents,
own-regulated SOD and GSH-PX activities in Cisp-resistant
W620 cells
To investigate the effect of salinomycin on the plasma mem-
rane instability, we conducted the LDH retention assay. Our
esults showed that the LDH release of Cisp-resistant SW620 cells
46.78 ± 3.82%) was higher than that of SW620 cells (19.32 ± 4.12%)
fter treatment with salinomycin for 48 h (p < 0.05) (Fig. 4A). It
emonstrated that salinomycin could greatly impact the plasma
embrane structure of Cisp-resistant SW620 cells. To better inves-igate the change of oxidative stress caused by salinomycin, we
etected MDA  contents, SOD and GSH-PX activities both in SW620
ells and Cisp-resistant SW620 cells. Compared to original SW620
ells, the MDA  contents in Cisp-resistant SW620 cells increased620 cells were compared, and the results showed that salinomycin was extremely
inomycin treatment, the expressing levels of Caspase-3, Caspase-8, Caspase-9 and
lls, while Bcl-2 mRNA expression was down-regulated. (* p < 0.05).
signiﬁcantly (p < 0.05) (Fig. 4B), while SOD and GSH-PX activities
were decreased (p < 0.05) (Fig. 4C and D).
3.7. Cisp-resistant SW620 cells were extremely sensitive to
salinomycin by IC50 comparison
By CCK-8 assay, the cell growth inhibiting curves were drawn
and showed in Fig. 4E, and the IC50 values of salinomycin both
in SW620 and Cisp-resistant SW620 cells were calculated. As
shown in Fig. 4F, the IC50 of salinomycin in SW620 cells was
1.54 ± 0.23 mol/l, while that in Cisp-resistant SW620 cells was
only 0.32 ± 0.05 mol/l (p < 0.05). This data indicated that Cisp-
resistant SW620 cells were relatively sensitive to salinomycin
compared to SW620 cells.
3.8. Salinomycin inﬂuenced mRNA and protein expressions of
Caspase-3, Caspase-8, Caspase-9, BCL-2 and Bax in Cisp-resistant
SW620 cells
We further compared the Caspase-3, Caspase-8, Caspase-9, BCL-
2 and Bax mRNA expressions in SW620 cells and Cisp-resistant
SW620 cells. Compared to SW620 cells, we found that salino-
mycin could up-regulate Caspase-3, Caspase-8, Caspase-9 and Bax
mRNA expressions in Cisp-resistant SW620 cells (p < 0.05). On the
contrary, the Bcl-2 mRNA expressions in Cisp-resistant SW620
cells were down-regulated (p < 0.05). Furthermore, the ratio of Bcl-
2/Bax in Cisp-resistant SW620 cells was signiﬁcantly disordered
(Fig. 4G). To gain further insight into the protein expressing lev-
els of Caspase-3, Caspase-8, Caspase-9, BCL-2 and Bax in SW620
cells and Cisp-resistant SW620 cells, western blot was performed.
As expected, salinomycin increased the protein expressions of
Caspase-3, Caspase-8, Caspase-9 and Bax, but decreased Bcl-2 pro-
tein expression in Cisp-resistant SW620 cells, compared to SW620
cells (Fig. 5).4. Discussion
Cisplatin is one the most commonly used chemotherapeutic
agents in treatment of colorectal cancers. The cytotoxic effects of
144 J. Zhou et al. / Toxicology Lette
Fig. 5. Western blot analysis showed that salinomycin could increased the protein
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vation and apoptosis by cellular zinc ﬂuxes and zinc deprivation: a review.xpressions of Caspase-3, Caspase-8, Caspase-9 and Bax, but decreased Bcl-2 protein
xpressions in Cisp-resistant SW620 cells, compared to SW620 cells.
isplatin are mediated by its interaction with DNA, resulting in
he formation of DNA adducts which activate several signal trans-
uction pathways and lead to cell apoptosis (Crul et al., 2002).
hough it’s widely indications and satisfactory anti-cancer effects
n colorectal cancers, we still encounter lots of cisplatin-resistant
ases. So there is an urgent need for a better understanding of the
olecular mechanisms underlying the cisplatin resistance. Barr
t al. illustrated that cisplatin-resistant non-small cell lung can-
er cells showed a characteristic of stem cells, and that might be
he direct cause of cell resistance (Barr et al., 2013). Wintzell et al.
lso found that repeated cisplatin treatment could induce a multi-
esistant tumor cell population with stem cell features (Wintzell
t al., 2012). These stem-like cells are likely to maintain a relative
uiescent state, have the natural features that could be resistant
o chemotherapy, and overexpress some drug-resistance related
roteins, which efﬁciently transport the chemotherapeutics out of
ancer cells (Barr et al., 2013; Moore and Lyle, 2011).
In our present study, we compared the original SW620 cells
nd Cis-resistant SW620 cells, and found that Cisp-resistant SW620
ells also displayed a stem-like signature in colorectal cancers with
ncreased expressions of some stem cell related transcription fac-
ors (Sox2, Oct4, Nanog, Klf4 and Hes1), surface biomarkers (CD24,
D26, CD44, CD133, CD166, Lgr5), functional markers (ALDH1A1,
LDH1A3), and drug resistance-related proteins (MDR1, MRP1 and
RP) (Fig. 2D and E). We  also conﬁrmed that the Cisp-resistant
W620 cells presented a relative quiescent state (G0/G1 arrest)
ompared to the original cells (Fig. 3A). Though there was  no dif-
erence in ALDH2 mRNA expressions between original SW620 cells
nd Cisp-resistant SW620 cells (p > 0.05), the reason might be that
he main coding gene for ALDH is ALDH1 isoforms (ALDH1A1 and
LDH1A3) (Moreb et al., 2007). All data indicated that the potential
tem-like traits of Cisp-resistant SW620 cells might be one of the
ain factors for drug-resistance.
Previously studies have showed that salinomycin could specif-
cally induced cell apoptosis of CSCs. But until now, reports that
eveal the relationship between salinomycin and drug-resistant
ancer cells are rare. Zhang et al. found that salinomycin could
igniﬁcantly and effectively inhibit the cisplatin-resistant human
varian cancer cell line growth through the induction of apoptosis,
otentially associated with the p38 MAPK activation (Zhang et al.,
013). In our present study, we compared the IC50 values in orig-
nal SW620 cells and Cisp-resistant SW620 cells, and found that
alinomycin was extremely sensitive to the Cisp-resistant SW620
ells (Fig. 4E and F). Meanwhile, by ﬂow cytometry analysis, sali-
omycin did not inﬂuence the cell cycle both in original SW620rs 222 (2013) 139– 145
cells and Cisp-resistant SW620 cells (Fig. 3A). But after salinomycin
treatment, the cell apoptotic rate of Cisp-resistant SW620 cells was
signiﬁcantly increased (Fig. 3B and C). We  speculated that salino-
mycin could greatly induce the apoptpsis of Cisp-resistant cells, as
these drug-resistant colorectal cancer cells might presented more
stem-like signatures.
To further explore the potential mechanisms that salinomycin
could speciﬁcally induce apoptosis in drug-resistant cells, we
detected some classical and speciﬁc oxidative stress indicators that
could reﬂected the levels of lipid peroxidation in cells, such as
LDH release, MDA  contents, SOD and GSH-PX activities (Cong et al.,
2012; Del Rio et al., 2005; Qin et al., 2008). Our results demonstrated
that salinomycin could cause abundant of lipid peroxides with
increased LDH release and MDA  contents in Cisp-resistant SW620
cells. Salinomycin also down-regulated SOD and GSH-PX activities
in Cisp-resistant SW620 cells (Fig. 4A, B, C and D). We  also detected
the downstream apoptosis-related key genes, such as Caspase-3,
Caspase-8, Caspase-9, Bcl-2 and Bax. A large number of studies
have showed that Bcl2 is a key anti-apoptotic gene, while Caspase-
3, Caspase-8, Caspase-9 and Bax are considered as pro-apoptotic
genes, the decreased ratio of Bcl2/Bax is involved in different kinds
of tumor cell apoptosis (Chai et al., 1999; Mohan et al., 2012; Wyllie,
2010). Our results showed that salinomycin could effectively up-
regulate both mRNA and protein expressing levels of caspase-3,
Caspase-8, caspase-9 and Bax, but down-regulated the Bcl-2 mRNA
and protein expressions in Cisp-resistant SW620 cells (Fig. 4G and
Fig. 5). Meanwhile, the ratio of Bcl-2/Bax in Cisp-resistant SW620
cells was seriously disordered. Our study manifested that high
levels of oxidative stress caused by accumulated reactive oxygen
species and dysregulations of apoptosis-related genes or proteins
might ultimately led to apoptosis in Cisp-resistant SW620 cells.
In summary, we ﬁrstly obtained Cisp-resistant SW620 cells from
original colorectal cancer cells by repeated treatment with 5 mol/l
of cisplatin. These Cisp-resistant SW620 cells, which maintained a
relative quiescent state and displayed stem-like signatures, were
relatively sensitive to salinomycin. Salinomycin could speciﬁcally
increase the apoptotic rate of Cisp-resistant SW620 cells, by accu-
mulated reactive oxygen species and down regulation of some
apoptosis-related genes or proteins. These ﬁndings will provide
new clue for novel and selective chemotherapy on drug-resistant
colorectal cancer cells.
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